MiMedx Group Dirección

Dirección controles de criterios 1/4

El CEO de MiMedx Group's es Joe Capper , nombrado en Jan 2023, tiene una permanencia de 1.25 años. compensación anual total es $20.76M, compuesta por 3.3% salario y 96.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.068% de las acciones de la empresa, por valor de $627.01K. La antigüedad media del equipo directivo y de la junta directiva es de 1.6 años y 3.8 años, respectivamente.

Información clave

Joe Capper

Chief Executive Officer (CEO)

US$20.8m

Compensación total

Porcentaje del salario del CEO	3.3%
Permanencia del CEO	1.3yrs
Participación del CEO	0.07%
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	3.8yrs

Actualizaciones recientes de la dirección

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

May 21

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

May 14

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Mar 27

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Jan 05

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Dec 18

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Joe Capper en comparación con los beneficios de MiMedx Group?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$68m
Dec 31 2023	US$21m	US$678k	US$56m

Compensación vs. Mercado: La compensación total de Joe($USD20.76M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD3.42M).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Joe con los resultados de la empresa.

CEO

Joe Capper (59 yo)

1.3yrs

Permanencia

US$20,756,346

Compensación

Mr. Joseph H. Capper, also known as Joe, serves as Chief Executive Officer and Director of MiMedx Group, Inc. since January 30, 2023. He is Director of Neuronetics, Inc. from January 01, 2023. He serves as...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Joseph Capper	CEO & Director	1.3yrs	US$20.76m	0.068% $ 775.0k
Douglas Rice	Chief Financial Officer	less than a year	US$2.75m	0.0034% $ 38.8k
William Hulse	General Counsel & Chief Administrative Officer	4.4yrs	US$1.91m	0.17% $ 1.9m
Scott Turner	Senior Vice President of Operations & Procurement	1.1yrs	US$619.46k	0% $ 0
Matthew Notarianni	Head of Investor Relations	1.6yrs	sin datos	sin datos
Mark Graves	Senior VP & Chief Compliance Officer	1.1yrs	sin datos	sin datos
Hilary Dixon	Vice President of Investor Relations & Corporate Strategic Communications	no data	sin datos	sin datos
Kate Surdez	Chief Human Resources Officer	1.8yrs	sin datos	sin datos
David Mason	Chief Medical Officer	5.4yrs	sin datos	sin datos
Robert Stein	President of Regenerative Medicine & Biologics Innovation	3.8yrs	US$1.74m	sin datos
Rebeccah J. Brown	Vice President of Global Regulatory Affairs	11.1yrs	US$198.47k	sin datos

1.7yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MDXG no se considera experimentado ( 1.6 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Joseph Capper	CEO & Director	1.3yrs	US$20.76m	0.068% $ 775.0k
Martin Sutter	Independent Preferred Director	3.8yrs	sin datos	0.00034% $ 3.9k
James Bierman	Independent Director	4.9yrs	US$278.43k	0.086% $ 989.0k
William Hawkins	Independent Preferred Director	3.8yrs	US$264.50k	0.081% $ 921.2k
James Andrews	Member of Medical Advisory Board	no data	sin datos	sin datos
Michael Giuliani	Independent Director	3.5yrs	US$267.00k	0.066% $ 750.0k
Thomas Zdeblick	Member of Medical Advisory Board	no data	sin datos	sin datos
Cato Laurencin	Independent Director	3.5yrs	US$282.14k	0.066% $ 750.0k
K. Newton	Independent Director	4.9yrs	US$1.35m	0.22% $ 2.5m
Robert Guldberg	Member of Regenerative Medicine Scientific Advisory Board	no data	sin datos	sin datos
Glenn Gaston	Member of Medical Advisory Board	no data	sin datos	sin datos
M. Behrens Wilsey	Independent Chairman of the Board	4.9yrs	US$340.50k	sin datos

3.8yrs

Permanencia media

69yo

Promedio de edad

Junta con experiencia: La junta directiva de MDXG se considera experimentada (3.8 años de antigüedad promedio).

MiMedx Group Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

Insider recently sold US$162k worth of stock

MiMedx Group, Inc. Announces Appointment of New Independent Directors

Insider recently sold US$250k worth of stock

Mimedx Group, Inc. Announces Retirement of Mr. William Phelan as Chief Accounting Officer

MiMedx Group, Inc. Announces Chief Financial Officer Changes

Recent updates

MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Investor sentiment improves as stock rises 18%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc., Annual General Meeting, Jun 05, 2024

MiMedx Group, Inc. to Report Q1, 2024 Results on Apr 30, 2024

MiMedx Group, Inc. Provides Update on AXIOFILL Request for Designation (RFD) from FDA

Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet

Insider recently sold US$162k worth of stock

Mimedx Introduces E-Commerce and Account Management Platform

MiMedx Group, Inc. Announces Appointment of New Independent Directors

Full year 2023 earnings: EPS exceeds analyst expectations

New minor risk - Insider selling

Insider recently sold US$250k worth of stock

MiMedx Group, Inc. to Report Q4, 2023 Results on Feb 28, 2024

We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Forecast breakeven date pushed back to 2024

MiMedx Group, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Mimedx Group, Inc. Announces Launch of Epieffect

Mimedx Group, Inc. Announces Retirement of Mr. William Phelan as Chief Accounting Officer

Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?

MiMedx Group, Inc. Provides Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.01 (vs US$0.11 loss in 2Q 2022)

Price target increased by 8.0% to US$10.17

Forecast breakeven date moved forward to 2023

MiMedx Group, Inc. Announces Chief Financial Officer Changes

Consensus EPS estimates upgraded to US$0.10 loss

Price target decreased by 9.3% to US$9.29

Insider recently sold US$84k worth of stock

Insider notifies of intention to sell stock

MiMedx Group, Inc., Annual General Meeting, Jun 13, 2023

Insider recently sold US$276k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?

Insider notifies of intention to sell stock

Chief Financial Officer recently sold US$85k worth of stock

Chief Financial Officer notifies of intention to sell stock

MiMedx Group, Inc. Announces Chief Executive Officer Changes

MiMedx Group, Inc. to Report Q4, 2022 Results on Mar 01, 2023

MiMedx Group, Inc. Appoints Ricci S. Whitlow as Chief Operating Officer

Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?

MiMedx Group, Inc. Announces the Resignation of Rohit Kashyap as President, Wound Care and Surgical, Effective January 3, 2023

Price target decreased to US$10.25

High number of new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

MiMedx Group, Inc. Provides Net Sales Guidance for the Fourth Quarter and Full Year 2022

MiMedx Group, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Price target decreased to US$10.25

Mimedx Group, Inc. Announces Management Changes

High number of new directors

MiMedx Group, Inc. Announces Launch of AXIOFILL

MiMedx Group, Inc. Announces Launch of AMNIOEFFECT™

Insider recently sold US$94k worth of stock

MIMEDX EPIFIX® Receives Reimbursement Approval in Japan

MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX

Consensus EPS estimates fall by 12%

MiMedx Group, Inc. Provides Sales Guidance for the Year Ending December 31, 2022

MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range

Insider recently sold US$71k worth of stock

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

MiMedx Group, Inc. Reaffirms Revenue Guidance for 2022

High number of new directors

MiMedx Group, Inc. Forms Regenerative Medicine Scientific Advisory Board Comprised of Renowned Industry and Academic Experts

MiMedx Group, Inc. to Report Q2, 2022 Results on Aug 02, 2022